Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

• Main Authors: Deborah Watson-Jones, ProfPhD (Author), John Changalucha, MSc (Author), Hilary Whitworth, PhD (Author), Ligia Pinto, PhD (Author), Paul Mutani, MD (Author), Jackton Indangasi, MSc (Author), Troy Kemp, PhD (Author), Ramadhan Hashim, BSc (Author), Beatrice Kamala, Dip (Author), Rebecca Wiggins, PhD (Author), Twaib Songoro, BA (Author), Nicholas Connor, MSc (Author), Gladys Mbwanji, MSc (Author), Miquel A Pavon, PhD (Author), Brett Lowe, MSc (Author), Devis Mmbando, BSc (Author), Saidi Kapiga, ProfPhD (Author), Philippe Mayaud, ProfMD (Author), Silvia de SanJosé, MD (Author), Joakim Dillner, ProfPhD (Author), Richard J Hayes, ProfDSc (Author), Charles J Lacey, ProfMD (Author), Kathy Baisley, MSc (Author)
• Format: Book
• Published: Elsevier, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: An estimated 15% of girls aged 9-14 years worldwide have been vaccinated against human papillomavirus (HPV) with the recommended two-dose or three-dose schedules. A one-dose HPV vaccine schedule would be simpler and cheaper to deliver. We report immunogenicity and safety results...